Ex vivo reversal of heparin-mediated cardioprotection by heparinase after ischemia and reperfusion

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 3, 1999, Pages 1041-1047

  Kilgore, Kenneth S ^a   Tanhehco, Elaine J ^a   Naylor, Keith B ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; HEPARIN; HEPARIN LYASE; MYOSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME RELEASE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ANIMALS; ANTICOAGULANTS; CREATINE KINASE; HEPARIN; HEPARIN ANTAGONISTS; HEPARIN LYASE; IODINE RADIOISOTOPES; LANTHANUM; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RABBITS;

EID: 0032813027     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM and Lucchesi BR (1995) Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 29:629-636.
2. Castellot JJ, Wong K, Herman B, Hoofer RJ, Albertini DF, Wright TC, Caleb BJ and Karnovsky MJ (1985) Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 124:13-20.
3. Crarnowska E and Karwatowska PE (1995) Ultrastructural demonstration of endothelial glycocalyx disruption in the reperfused rat heart: Involvement of oxygen free radicals. Basic Res Cordial 90:357-364.
4. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Greenfield LJ and Wakefield TW. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis (1998) J Vasc Surg 28:848-854.
5. Ecker EE and Gross P (1929) Anticomplementary power of heparin. J Infect Dis 44:250-253.
6. Ecker EE and Pillemer L (1941) Anticoagulants and complementary activity. J Immunol 40:73-80.
7. Edens RE, Linhardt RJ and Weiler JM (1993) Heparin is not just an anticoagulant anymore: Six and one-half decades of studies on the ability of heparin to regulate complement activity, in Complement Today (Cruse JM and Lewis RE Jr eds) vol 1, pp 96-130, Karger, Basel.
8. Evans RC, Wong VS, Morris AI and Rhodes JM (1997) Treatment of corticosteroid-resistant ulcerative colitis with heparin-a report of 16 cases. Aliment Pharmacol Ther 11:1037-1040.
9. Friedrichs GS, Kilgore KS, Manley PJ, Gralinski MR and Lucchesi BR (1994) Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res 75:701-710.
10. Gorog P, Pearson JD and Kakkar W (1988) Generation of reactive oxygen metabolites by phagocytosing endothelial cells. Atherosclerosis 72:19-27.
11. Gralinski MR, Driscoll EM, Friedrichs GS, DeNardis MR and Lucchesi BR (1996) Reduction of myocardial necrosis after glycosaminoglycan administration: Effect of a single intravenous administration of heparin or N-acetylheparin 2 h before regional ischemia and reperfusion. J Cardiovasc Pharmacol Therapeut 1:219-228.
12. Haack DW, Bush LR, Shlafer M and Lucchesi BR (1981) Lanthanum staining of coronary microvascular endothelium: Effects of ischemic reperfusion, propranolol and atenolol. Microvasc Res 21:362-376.
13. Haber E, Katus HA, Hurrell LG, Matsueda GR, Ehrlich P, Zurawski VR and Khaw BA (1982) Detection and quantification of myocardial cell death: Application of monoclonal antibodies specific for cardiac myosin. J Mol Cell Cardiol 14(Suppl 3):139-146.
14. Han RO, Ettenson DS, Koo EW and Edelman ER (1997) Heparin/heparan sulfate chelation inhibits control of vascular repair by tissue-engineered endothelial cells. Am J Physiol 273:H2585-H2595.
15. Hayward R, Nossuli TO and Lefer AM (1997) Heparinase III exerts endothelial and cardioprotective effects in feline myocardial ischemia-reperfusion injury. J Pharmacol Exp Ther 283:1032-1038.
16. Hiebert LM and Jaques LB (1976a) Heparin uptake on endothelium. Artery 2:26-37.
17. Hiebert LM and Jaques LB (1976b) The observation of heparin on endothelium after injection. Thromb Res 8:195-204.
18. Hobson RW, Wright JG, Fox D and Kerr JC (1988) Heparinization reduces endothelial permeability and hydrogen ion accumulation in a canine skeletal muscle ischemia-reperfusion model. J Vasc Surg 7:585-591.
19. Hoffstein ST, Gennaro DE, Fox AC, Hirsch J, Streuli F and Weissmann G (1975) Colloidal lanthanum as a marker for impaired plasma membrane permeability in ischemic dog myocardium. Am J Pathol 79:206-217.
20. Homeister JW, Satoh PS and Lucchesi BR (1992) Effects of complement activation in the isolated heart-role of the terminal complement components. Circ Res 71:303-319.
21. Hoogenwerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, Power CA and Wells TN (1997) Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 36:13570-13578.
22. Jokelainen PT, Haack DW and Rhodin JAG (1976) Permeability of arterial capillary endothelium, in Microcirculation (Grayson J and Zingg W eds) vol 2, pp 77-78, Plenum, New York.
23. Keller FG, DeFazio J, Jencks F, Steiner M, Rogers J and Ritchey AK (1998) The use of heparinase to neutralize residual heparin in blood samples drawn through pediatric indwelling central venous catheters. J Pediatrics 132:165-167.
24. Khaw BA, Fallen JT, Beller GA and Haber E (1979) Specificity of localization of myosin-specific antibody fragment in experimental myocardial infarction: Histlogic, histochemical, autoradiographic and scintigraphic studies. Circulation 60:1527-1531.
25. Kouretas PC, Kim YD, Cahill PA, Myers AK, To LN, Wang Y-N, Sitzmann JV and Hannan RL (1999) Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in the dog. Circulation 99:1062-1068.
26. Kouretas PC, Myers AK, Kim YD, Cahill PA, Myers JL, Wang YN, Sitzmann JV, Wallace RB and Hannan RL (1998) Heparin and non-anticoagulant heparin preserve regional myocardial contractility after ischemia-reperfusion injury: Role of nitric oxide. J Thorac Cardiovasc Surg 115:440-449.
27. Marcum JA and Rosenberg RD (1989) Role of endothelial cell surface heparin-like polysaccharides. Ann NY Acad Sci 556:81-94.
28. Michelsen LG, Kikura M, Levy JH, Lee MK, Lee KC, Zimmermann JJ and Szlam F (1997) Heparinase I (neutralase) reversal of systemic anticoagulation. Anesthesiology 85:339-346.
29. Park JL, Kilgore KS, Naylor KB, Booth EA, Murphy KL and Lucchesi BR (1999) N-Acetylheparin pretreatment reduces infarct size in the rabbit. Pharmacology 58:120-131.
30. Ruoslahti E and Yamaguchi Y (1991) Proteoglycans as modulators of growth factor activities. Cell 64:867-869.
31. Sakahara H, Endo K, Nakashima T, Koizumi M, Kunimatsu M, Kawamura Y, Ohta H, Nakamura T, Tanaka H, Kotoura Y, Yamamuro T, Hosoi S, Toyama S and Torizuka K (1987) Localization of human osteogeneic sarcoma xenographs in nude mice by a monoclonal antibody labeled with radioiodine and indium-111. J Nucl Med 28:342-348.
32. Saliba MJ Jr (1997) The effects and uses of heparin in the care of burns that improves treatment and enhances the quality of life. Acta Chirurgiae Plasticae 39:13-16.
33. Shastri KA, Logue GL, Stern MP, Rehman S and Raza S (1997) Complement activation by heparin-protamine complexes during cardiopulmonary bypass: Effect of C4A null allele. J Thorac Cardiovasc Surg 114:482-488.
34. Shell WE, Kjekshus JK and Sobel BE (1971) Quantitative assessment of the extent of myocardial function in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase activity. J Clin Invest 50:2614-2625.
35. Sunnergren KP, Fairman RP, DeBlois GG and Glauser FL (1987) Effects of protamine, heparinase and hyaluronidase on endothelial permeability and surface charge. J Appl Physiol 63:1987-1992.
36. Szasz G, Gruber W and Bernt E (1976) Creatine kinase in serum. I. Determination of optimum reaction conditions. Clin Chem 22:650-656.
37. Weihe E, Hartschuyh W, Metz J and Bruhl U (1977) The use of ionic lanthanum as a diffusion tracer and as a marker of calcium binding sites. Cell Tissue Res 178:285-302.
38. Weiler JM, Yurt RW, Fearon DT and Austen KF (1978) Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J Exp Med 147:409-421.
39. Yasojima K, Kilgore KS, Washington RA, Lucchesi BR and McGeer PL (1998) Complement gene expression by rabbit heart: Upregulation by ischemia and reperfusion. Circ Res 82:1224-1230.